University of Southern California
USC/Norris Comprehensive Cancer Center
If you are a patient, please contact The Doctors of USC at 800-USC-CARE.

Details for trial 16M-08-1


 
Description: A Phase I/II, Multi-Center, Open-Label, Dose-Escalation Study of Elotuzumab (Humanized anti-CS1 Monoclonal IgG1 antibody, formerly HuLuc63) and Bortezomib in Subjects with Multiple Myeloma Following One to Three Prior Therapies.
Status: Open
Randomized? No


Researchers  
Principal InvestigatorTitle
Ann MohrbacherM.D.

Data Management
NameTitle
Lori VergaraR.N.
Yvonne AvilaD.M.
Rebecca AmezcuaR.N.


You may participate in this study if:
(No criteria found)

You may not participate in this study if:
(No criteria found)

For further information on, or to sign up for this study, please contact the Clinical Investigation Support Office at (323) 865-0451 or the Principal Investigator noted above.